Home » Stocks » TELA

TELA Bio, Inc. (TELA)

Stock Price: $15.26 USD -0.24 (-1.55%)
Updated Jul 23, 2021 4:00 PM EDT - Market closed
Market Cap 220.36M
Revenue (ttm) 20.36M
Net Income (ttm) -29.71M
Shares Out 14.44M
EPS (ttm) -2.17
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day July 23
Last Price $15.26
Previous Close $15.50
Change ($) -0.24
Change (%) -1.55%
Day's Open 15.55
Day's Range 15.26 - 15.53
Day's Volume 4,071
52-Week Range 11.03 - 18.00

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Mr. Paul Wilson, Consultant General Surgeon, successfully completes complex hernia repair with minimally invasive approach Mr. Paul Wilson, Consultant General Surgeon, successfully completes complex her...

3 days ago - GlobeNewsWire

OEG, EAF, RARE, EGRX, and TELA have been added to the Zacks Rank #5 (Strong Sell) List on June 18, 2021

Other stocks mentioned: EAF, EGRX, OEG, RARE
1 month ago - Zacks Investment Research

MALVERN, Pa., June 14, 2021 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on designing, developing, and marketing innovative tissue reinforcement mat...

1 month ago - GlobeNewsWire

MALVERN, Pa., May 21, 2021 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on designing, developing, and marketing innovative tissue reinforcement mate...

2 months ago - GlobeNewsWire

TELA Bio Inc (NASDAQ: TELA) has launched its second post-market study, BRAVO II, to evaluate the clinical performance of OviTex Reinforced Tissue Matrices in the robotic repair of ventral hernias. The s...

2 months ago - Benzinga

MALVERN, Pa., May 19, 2021 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on designing, developing, and marketing innovative tissue reinforcement mate...

2 months ago - GlobeNewsWire

TELA Bio, Inc. (TELA) delivered earnings and revenue surprises of -27.27% and 4.02%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

Shares of TELA Bio (NASDAQ:TELA) rose in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share were up 11.11% year over year to ($0.56), which missed the estim...

2 months ago - Benzinga

MALVERN, Pa., May 13, 2021 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA") (Nasdaq: TELA), a commercial stage medical technology company focused on designing, developing, and marketing innovative tissue rei...

2 months ago - GlobeNewsWire

TELA Bio, Inc. (TELA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

MALVERN, Pa., April 29, 2021 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on designing, developing, and marketing innovative tissue reinforcement ma...

2 months ago - GlobeNewsWire

TELA Bio, Inc. (TELA) delivered earnings and revenue surprises of -5.88% and 1.20%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

4 months ago - Zacks Investment Research

Shares of TELA Bio (NASDAQ:TELA) were unchanged after the company reported Q4 results. Quarterly Results Earnings per share increased 55.74% over the past year to ($0.54), which missed the estimate of (...

4 months ago - Benzinga

MALVERN, Pa., March 24, 2021 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on designing, developing, and marketing innovative tissue reinforcement ma...

4 months ago - GlobeNewsWire

MALVERN, Pa., Feb. 04, 2021 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on designing, developing, and marketing innovative tissue reinforcement mat...

5 months ago - GlobeNewsWire

MALVERN, Pa., Jan. 14, 2021 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA") (Nasdaq: TELA), a commercial-stage medical technology company focused on designing, developing and marketing a new category of tis...

6 months ago - GlobeNewsWire

Bruce Freedman, M.D. joins innovative MedTech company to advocate for more natural surgical hernia mesh options

6 months ago - GlobeNewsWire

MALVERN, Pa., Nov. 24, 2020 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on designing, developing and marketing a new category of tissue reinforceme...

8 months ago - GlobeNewsWire

TELA Bio, Inc. (TELA) CEO Tony Koblish on Q3 2020 Results - Earnings Call Transcript

8 months ago - Seeking Alpha

Shares of TELA Bio (NASDAQ:TELA) were flat after-market trading after the company reported Q3 results. Quarterly Results Earnings per share increased 97.65% over the past year to ($0.53), which missed t...

8 months ago - Benzinga

MALVERN, Pa., Nov. 10, 2020 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on designing, developing and marketing a new category of tissue reinforceme...

8 months ago - GlobeNewsWire

MALVERN, Pa., Nov. 9, 2020 /PRNewswire/ -- TELA Bio, Inc. ("TELA"), an innovative medtech company focused on solving the unmet needs in soft-tissue reconstruction, announced today that it will be featur...

8 months ago - PRNewsWire

MALVERN, Pa., Oct. 21, 2020 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (Nasdaq: TELA), a commercial stage medical technology company focused on designing, developing and marketing a new category of...

9 months ago - GlobeNewsWire

MALVERN, Pa., Sept. 25, 2020 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on designing, developing and marketing a new category of tissue reinforc...

9 months ago - GlobeNewsWire

MALVERN, Pa., Sept. 02, 2020 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on designing, developing and marketing a new category of tissue reinforc...

10 months ago - GlobeNewsWire

TELA Bio, Inc. (TELA) CEO Tony Koblish on Q2 2020 Results - Earnings Call Transcript

11 months ago - Seeking Alpha

MALVERN, Pa., Aug. 12, 2020 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA") (Nasdaq: TELA), a commercial stage medical technology company focused on designing, developing and marketing a new category of t...

11 months ago - GlobeNewsWire

MALVERN, Pa., July 30, 2020 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA") (Nasdaq: TELA), a commercial-stage medical technology company focused on designing, developing and marketing a new category of t...

11 months ago - GlobeNewsWire

MALVERN, Pa., July 23, 2020 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (Nasdaq: TELA), a commercial stage medical technology company focused on designing, developing and marketing a new category ...

1 year ago - GlobeNewsWire

MALVERN, Pa., July 09, 2020 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on designing, developing and marketing a new category of tissue reinforce...

1 year ago - GlobeNewsWire

MALVERN, Pa., June 30, 2020 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (“TELA”), a commercial-stage medical technology company focused on designing, developing and marketing a new category of tissue reinforce...

1 year ago - GlobeNewsWire

MALVERN, Pa., June 25, 2020 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on designing, developing and marketing a new category of tissue reinforce...

1 year ago - GlobeNewsWire

MALVERN, Pa., June 23, 2020 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on designing, developing and marketing a new category of tissue reinforce...

1 year ago - GlobeNewsWire

MALVERN, Pa., June 22, 2020 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA") (Nasdaq: TELA), a commercial stage medical technology company focused on designing, developing and marketing a new category of t...

1 year ago - GlobeNewsWire

MALVERN, Pa., June 15, 2020 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA") (Nasdaq: TELA), a commercial stage medical technology company focused on designing, developing and marketing a new category of t...

1 year ago - GlobeNewsWire

TELA Bio, Inc. (TELA) CEO Antony Koblish on Q1 2020 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

MALVERN, Pa., May 12, 2020 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA") (Nasdaq: TELA), a commercial stage medical technology company focused on designing, developing and marketing a new category of ti...

1 year ago - GlobeNewsWire

MALVERN, Pa., April 23, 2020 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (Nasdaq: TELA), a commercial stage medical technology company focused on designing, developing and marketing a new category...

1 year ago - GlobeNewsWire

TELA Bio, Inc. (TELA) CEO Antony Koblish on Q4 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

MALVERN, Pa., Feb. 04, 2020 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (“TELA”) (Nasdaq: TELA), a commercial stage medical technology company focused on designing, developing and marketing a new category of t...

1 year ago - GlobeNewsWire

MALVERN, Pa., Jan. 29, 2020 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (“TELA”) (Nasdaq: TELA), a commercial stage medical technology company focused on designing, developing and marketing a new category of t...

1 year ago - GlobeNewsWire

MALVERN, Pa., Jan. 10, 2020 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (“TELA”) (Nasdaq: TELA), a commercial stage medical technology company focused on designing, developing and marketing a new category of t...

1 year ago - GlobeNewsWire

MALVERN, Pa., Dec. 06, 2019 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (“TELA”) (Nasdaq: TELA), a commercial stage medical technology company focused on designing, developing and marketing a new category of t...

1 year ago - GlobeNewsWire

About TELA

TELA Bio, Inc., a medical technology company, focuses on the design, development, and marketing of tissue reinforcement materials to address unmet needs in soft tissue reconstruction. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine... [Read more...]

Industry
Medical Devices
IPO Date
Nov 8, 2019
Stock Exchange
NASDAQ
Ticker Symbol
TELA
Full Company Profile

Financial Performance

In 2020, TELA Bio's revenue was $18.21 million, an increase of 17.91% compared to the previous year's $15.45 million. Losses were -$28.79 million, 28.4% more than in 2019.

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for TELA Bio stock is "Buy." The 12-month stock price forecast is 20.00, which is an increase of 31.06% from the latest price.

Price Target
$20.00
(31.06% upside)
Analyst Consensus: Buy